Emmanuel Lacroix joined UCB Ventures in March 2017, as a founding partner. He is currently a member of the Board of Syndesi Therapeutics, a UCB spinout company that he helped to launch in early 2018. Syndesi Therapeutics develops novel therapeutics addressing cognitive deficits in, for example, people with Alzheimer’s Disease. Emmanuel also holds a Board observer position with Lumos Pharma, a company developing therapeutics for rare and neglected diseases, with focus on neurodevelopment disorders.
Emmanuel served as UCB’s Head of Business Development Neurology where he was instrumental to the execution of multiple partnership and license agreements, product acquisitions, and other investments, including the discovery collaboration with Q-State Bioscience in Epilepsy; the R&D partnership with Neuropore Therapies in Parkinson’s Disease; and the Series A and B investments in Lumos Pharma. In an earlier Sales and Global Marketing position, Emmanuel contributed to the coordination of global pre-launch activities for Vimpat® and the business planning for UCB’s other CNS products.
Before joining UCB, Emmanuel led multidisciplinary teams at Cellectis SA, a biotechnology start-up. He received an MBA from IMD (Switzerland), a PhD in Molecular Biology from ULB (Belgium) based on protein engineering research conducted at the European Molecular Biology Laboratory (Germany), and a MSc in Biochemistry from the ULG (Belgium).